Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients

Arthritis and Rheumatism

Volumn 64, Issue 2, 2012, Pages 418-422

  Gillespie, Justin ^a   Savic, Sinisa ^a   Wong, Chi ^a   Hempshall, Aiden ^a   Inman, Martyn ^a   Emery, Paul ^a   Grigg, Ronald ^a   McDermott, Michael F ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 6; MI 192; TRICHOSTATIN A; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS;

AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INTERFERON-GAMMA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED;

EID: 84863395477     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33382     Document Type: Article

References (11)

1. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P,. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-74. (Pubitemid 350180008)
2. Choo QY, Ho PC, Lin HS,. Histone deacetylase inhibitors: new hope for rheumatoid arthritis? Curr Pharm Des 2008; 14: 803-20. (Pubitemid 351751810)
3. Dinarello CA, Fossati G, Mascagni P,. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med 2011; 17: 333-52.
4. Yang X, Seto E,. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007; 26: 5310-8. (Pubitemid 47255917)
5. Karagianni P, Wong J,. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 2007; 26: 5439-49. (Pubitemid 47255926)
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
7. Huber LC, Brock M, Hemmatazad H, Giger OT, Moritz F, Trenkmann M, et al. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 2007; 56: 1087-93. (Pubitemid 46608633)
8. Myzak MC, Tong P, Dashwood W, Dashwood RH, Ho E,. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) 2007; 232: 227-34. (Pubitemid 46203291)
9. Kawabata T, Nishida K, Takasugi K, Ogawa H, Sada K, Kadota Y, et al. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-a in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 2010; 12: R133.
10. Lin H, Hu C, Chan H, Liew Y, Huang H, Lepescheux L, et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007; 150: 862-72. (Pubitemid 46536628)
11. Grabiec AM, Krausz S, de Jager W, Burakowski T, Groot D, Sanders ME, et al. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 2010; 184: 2718-28.